Testing the Persuasiveness of Pro-inoculation Arguments
NCT05804825 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 523
Last updated 2023-07-11
Summary
The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Parents will rate each message they see on measures of perceived argument strength/PME. Parents will also answer sociodemographic questions and then rank the believability of a set of anti-vaccine messages identified in a different study. Study findings will contribute valuable information to understanding the effectiveness of different inoculation messages.
Conditions
- Vaccination Hesitancy
- Human Papillomavirus Vaccination
- Vaccine Refusal
Interventions
- BEHAVIORAL
-
Argument inoculation messages
Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
- BEHAVIORAL
-
Simple forewarning message
Participants will be presented with a simple forewarning message.
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-05-04
- Primary Completion
- 2023-05-24
- Completion
- 2023-05-24
Countries
- United States
Study Locations
More Related Trials
-
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
NCT07348692 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
NCT06531538 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
NCT00546572 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults
NCT07059182 ·Status: COMPLETED ·Phase: PHASE1
-
Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting
NCT01787838 ·Status: COMPLETED ·Phase: NA
-
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT07035054 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age
NCT03313050 ·Status: COMPLETED ·Phase: PHASE2
-
Pneumonia Vaccine Education Intervention Study
NCT06136832 ·Status: COMPLETED ·Phase: NA
-
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT07025876 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
NCT01215175 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
NCT00744263 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)
NCT01513551 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
NCT03828617 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
NCT02531373 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
NCT05831124 ·Status: COMPLETED ·Phase: PHASE1
-
Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine
NCT04087460 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
NCT00427895 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
NCT03760146 ·Status: COMPLETED ·Phase: PHASE3
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
NCT04875533 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
NCT03547167 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
NCT03549208 ·Status: UNKNOWN ·Phase: PHASE1